Jazz Pharmaceuticals PLC

Roche announced that the FDA has approved expanded use of its PATHWAY HER2 (4B5) and VENTANA HER2 Dual ISH DNA Probe Cocktail tests as companion diagnostics to identify patients with HER2-positive metastatic gastroesophageal adenocarcinoma, including gastric, gastroesophageal junction, and esophageal adenocarcinoma, who may be eligible for treatment with Jazz Pharmaceuticals' ZIIHERA. This approval broadens the patient population eligible for HER2-targeted therapy, as previously no tests were approved to determine HER2 status in esophageal cancer. The tests, already widely used in breast and gastric cancers, are now part of Roche's comprehensive HER2 diagnostic portfolio, supporting personalized treatment approaches for this hard-to-treat disease.

Zymeworks shares climbed nearly 4.0% in pre-market trading as investors positioned themselves ahead of an important U.S. regulatory decision on zanidatamab, expected the following day. The FDA's PDUFA target action date for zanidatamab, a bispecific HER2-targeting antibody developed alongside Jazz Pharmaceuticals, is August 25, 2026, with the regulator reviewing the treatment for first-line HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma. Approval would immediately trigger a $250 million U.S. regulatory milestone payment, with up to an additional $190 million possible through regulatory milestones in other markets. Citi placed the stock on an upside 90-day catalyst watch earlier in August, while Truist and Wells Fargo have increased their price targets ahead of the PDUFA date. Zymeworks is also pursuing a roughly $929 million all-cash acquisition of Theravance Biopharma, expected to close in the second half of 2026, which would add commercial cash flows from the COPD treatment YUPELRI.

Several major acquisition deals were reported across sectors this week. Workday soared 19% on a report that private equity firm Silver Lake is in talks to buy the software company. Diversified Energy is in advanced talks to acquire Elliott Investment Management-backed oil and gas company Birch Resources for more than $1.7 billion in cash. EQT Infrastructure offered to buy Cleanaway Waste Management in a deal that values the Australian listed firm at about A$6.9 billion, or $4.9 billion. H.B. Fuller said it received an unsolicited proposal from Ancora Holdings to buy its building adhesives solutions business for $1.1 billion to $1.2 billion in cash. Aurora Cannabis soared 21% after Curaleaf Holdings said it plans to make a $4 per share takeover bid, with Curaleaf rising 6.7%. H&R Real Estate Investment Trust agreed to be acquired by GO Residential Real Estate Investment Trust and a consortium including Blackstone, Crestpoint, PSP Investments and a company controlled by members of the family of H&R CEO Tom Hofstedter in a deal valued at about C$6.7 billion, including assumed debt. Israeli AI startup Decart is in advanced talks to be sold to a major tech firm for $6 billion to $7 billion. Jazz Pharmaceuticals announced it will acquire privately held Actio Biosciences for $820 million upfront and up to $500 million in potential milestones.

AbCellera Biologics reported a net loss of roughly $55 million for the second quarter of 2026, up from a $35 million loss a year earlier, while total revenue dropped to approximately $4 million from $17 million. The company completed enrollment for the phase 2 study of ABCL-635 in treating hot flashes ahead of schedule, with top-line data expected soon, and secured new T-cell engager collaborations with Vertex and Jazz Pharmaceuticals that added over $110 million in upfront cash. AbCellera maintains a strong liquidity position with over $565 million in cash and equivalents plus roughly $110 million in committed government funding, providing a runway of at least three years. Research and development expenses increased by about $7 million year-over-year, and the company missed its internal goal of moving another program into IND-enabling activities in the first half of 2026. The upcoming phase 2 data for ABCL-635 carries scientific risks, including the unresolved question of whether blocking NK3R in the pre-optic nucleus is necessary for efficacy, and the company acknowledged a pronounced placebo response in similar trials.

Jazz Pharmaceuticals reported second-quarter 2026 revenue of $1.21 billion, exceeding analyst estimates of $1.12 billion and representing 15.5% year-on-year growth. The company raised its full-year revenue guidance to $4.68 billion at the midpoint, up from $4.38 billion and 3.6% above Wall Street expectations. Adjusted earnings per share came in at $5.71, missing the consensus estimate of $6.18 by 7.5%. Adjusted operating margin improved to 20.5% from negative 65.6% in the same quarter last year. Shares rose 2.5% to $257.97 following the announcement.

A slate of major companies including Palantir Technologies, Vertex Pharmaceuticals, and Diamondback Energy are set to report quarterly earnings after the market closes on August 3, 2026. Palantir is expected to post earnings per share of $0.28, a 115.38% jump from the same quarter last year, while Vertex's consensus stands at $4.30, up 7.50%. Diamondback Energy's forecast of $6.08 per share represents a 127.72% surge, though it missed estimates in the fourth quarter of 2025. Other notable reports include ONEOK with a consensus of $1.39, ON Semiconductor at $0.72, and SBA Communications at $2.76, which would mark a 12.93% decline year-over-year. Sterling Infrastructure is projected to deliver $5.00 per share, a 96.08% increase, and Jazz Pharmaceuticals is expected to swing to $5.06 per share after a large miss in the prior-year quarter.

Several biotech stocks reached 52-week highs on July 24, 2026, driven by upcoming quarterly reports and regulatory milestones. Inhibikase Therapeutics hit $2.53 after its lead candidate IKT-001 received FDA Orphan Drug designation for pulmonary arterial hypertension, with a global Phase 3 trial underway. Jazz Pharmaceuticals reached $256.75, supported by 19% first-quarter revenue growth to $1.1 billion and progress with Zanidatamab in breast cancer studies. Halozyme Therapeutics climbed to $82.99 following a 42% year-over-year revenue increase to $376 million in the first quarter and full-year guidance of $1.71 billion to $1.81 billion. Corcept Therapeutics touched $97.63, with first-quarter revenue rising to $164 million from $157 million a year earlier, ahead of its July 29 earnings report. Liquidia Corporation hit $91.10, buoyed by $130 million in first-quarter YUTREPIA sales and a net income of $52 million.

Jazz Pharmaceuticals has a positive Zacks Earnings ESP of +0.41% and a Zacks Rank #3, a combination that historically produces an earnings beat nearly 70% of the time. The company has beaten estimates in its last two quarters, with an average surprise of 18.03%, including a 35.76% beat last quarter when it reported $6.34 per share versus a $4.67 consensus. Its next earnings report is expected on August 3, 2026.

Strategic licensing agreements and acquisitions in antibody-drug conjugates and T-cell engager therapeutics continue to create significant value for platform companies well before pivotal clinical trials. The Jazz Pharmaceuticals–AbCellera collaboration exemplifies how differentiated antibody technologies can command substantial financial commitments prior to clinical development. VERAXA Biotech AG is positioning its technology platform across both ADCs and T-cell engagers, two modalities that continue to attract strategic partnerships. Recent transactions demonstrate that pharmaceutical companies are actively seeking access to differentiated antibody engineering capabilities rather than waiting for late-stage clinical assets.

Jazz Pharmaceuticals and AbCellera Biologics have entered a preclinical research collaboration to discover and develop next-generation T-cell-engaging multispecific antibodies for gastrointestinal cancers and other solid tumors. Under the deal, Jazz will make upfront payments totaling $56 million for the first two discovery programs, with an additional $28 million due upon initiation of a third program within 12 months. For each program Jazz advances, AbCellera is eligible to receive up to $792 million in option fees and milestone payments, plus tiered royalties on future net sales ranging from the mid-single digits to the low double digits. Jazz gains access to AbCellera's antibody discovery platform and T-cell engager technology, while retaining exclusive options to develop and commercialize resulting therapeutic antibodies. The collaboration may expand by up to two additional programs by mutual agreement.